Roche Obesity Drug Candidate Adds to Positive Data with New Trial Results
Dow Jones09-22
0649 GMT - Roche Holding achieved positive results in a study for its obesity drug candidate enicepatide in adults with diabetes and obesity, building on a previous trial that showed efficacy in obese patients without diabetes, Vontobel's Stefan Schneider says in a research note. Patients with Type 2 diabetes who are either overweight or obese are an inherently difficult-to-treat patient population, the analyst says. The combination of a good proportion of diabetics getting back to normalized glucose levels and achieving sustained weight loss with enicepatide give the drug a competitive profile, Schneider says.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments